Search
for
Sort by
Research 211–240 of 1000+
- A guide to the use of bioassays in exploration of natural resources
- Repurposing of H1-receptor antagonists (levo)cetirizine, (des)loratadine, and fexofenadine as a case study for systematic analysis of trials on clinicaltrials.gov using semi-automated processes with custom-coded software
- TRANSMEDCON 2022: E-Poster Abstracts
- Nanotechnological Interventions and Mechanistic Insights into Wound-Healing Events
- Isolation and HPLC Quantitative Determination of 5α-Reductase Inhibitors from Tectona grandis L.f. Leaf Extract
- Novel Cosmetic Uses of Botulinum Toxin in the Head and Neck
- Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario
- Industry updates in advanced therapy medicinal products and regenerative medicine – March 2026
- A randomized, double-blind controlled clinical study to evaluate the efficacy and safety of minoxidil topical 2% nanosuspension with aqueous base in the treatment of androgenetic alopecia areata
- Preparation and evaluation of a hair wax containing propolis and Eruca sativa seed oil for hair growth
- A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system
- Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia
- FDA Reports of Alopecia as an Adverse Event to Isotretinoin
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
- FDA declines approval of testosterone drug for third time
- Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
- FDA Approved pediatric antihypertensive agents
- (719) Signal Detection of Depression and Suicidality With the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database
- Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real‐World Pharmacovigilance Study
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
- Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)
- Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
- 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment